Conference Reports for NATAP

Back

The Liver Meeting San Francisco November 9-13 2018     Risk of Parkinson's Disease in Hepatitis C Patients Following Exposure to Direct-Acting Antiviral Treatment: An Analysis of US Administrative Claims Data - (06/10/19)   Limited sustained response and lack of HBsAg decline after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results of the prospective, randomized, open-label phase IV STOP study - (05/28/19)   Establishment of High Rates of Functional Control and Reversal of Fibrosis Following Treatment of HBeAg Negative Chronic HBV Infection with REP 2139-Mg / REP 2165-Mg, Tenofovir Disoproxil Fumarate and Pegylated Interferon Alpha-2a - (02/25/19)   Safety, Pharmacokinetics and Antiviral Activity of Novel HBV Capsid Assembly Modulator, JNJ-56136379, in Patients with Chronic Hepatitis B - (02/13/19)   FINAL RESULTS OF A PHASE 1B 28-DAY STUDY OF ABI-H0731, A NOVEL CORE INHIBITOR, IN NON-CIRRHOTIC VIREMIC SUBJECTS WITH CHRONIC HBV - (02/13/19)   First results with RNA interference (RNAi) in chronic hepatitis B (CHB) using ARO-HBV - (02/13/19)   TLR7 agonist RO7020531 triggers immune activation after multiple doses in chronic hepatitis B patients - (02/13/19)   Limited sustained response and lack of HBsAg decline after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results of the prospective, randomized, open-label phase IV STOP study - (02/13/19)   Interim results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with PEG-IFNαin patientswithchronicHBV/HDV co-infection - (02/13/19)   Systematic Review: Prevalence and Natural History of Alcohol Related Liver Disease - (01/07/19)   Inspired Study: Utilization Patterns and Outcomes of Elbasvir/Grazoprevir in the Real-World Greek Setting (interim analysis) - (01/07/19)   Trends in Causes of Mortality in Liver Transplantation Recipients: Comparison Among NASH, ALD, and HCV Cohorts - (01/04/19)   Health care costs associated with NAFLD - a long-term follow up study - (01/04/19)   Systematic Review: Prevalence and Natural History of Alcohol Related Liver Disease - (01/03/19)   Alcoholic Liver Disease Has Rapidly Emerged As the Leading Indication for Liver Transplant Evaluation - (01/03/19)   PREDICTABILITY OF SERUM HBcrAg, HBsAg AND INTERFERON INDUCIBLE PROTEIN 10 (IP10) LEVELS IN NON-CIRRHOTIC HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS WHO DISCONTINUE ENTECAVIR (ETV) OR TENOFOVIR (TDF) THERAPY: RESULTS FROM THE PROSPECTIVE DARING-B STUDY - (01/02/19)   KINETICS OF SERUM HEPATITIS B CORE RELATED ANTIGEN (HBcrAg) IN NON-CIRRHOTIC HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe-) PATIENTS WHO DISCONTINUE EFFECTIVE LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) - (01/02/19)   Safety, Pharmacokinetics, and Pharmacodynamics of Oral TLR8 Agonist GS-9688 in Patients With Chronic Hepatitis B: a Randomized, Placebo-Controlled, Double-blind Phase 1b Study - (12/31/18)   No Resistance to Tenofovir Alafenamide Detected Through 144 Weeks of Treatment in Patients With Chronic Hepatitis B - (12/31/18)   3-Year Efficacy and Safety of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in HBeAg-Negative and -Positive Patients With Chronic Hepatitis B - (12/31/18)   Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year After Switching to Tenofovir Alafenamide From Tenofovir Disoproxil Fumarate - (12/31/18)   Prediction and need for surveillance of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients of the PAGE-B cohort - (12/17/18)   Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV) - (12/17/18)   In Vitro Antiviral Activity and Mode of Action of JNJ-64530440, a Novel Potent Hepatitis B Virus Capsid Assembly Modulator in Clinical Development - (12/17/18)   ALT levels and risk of hepatocellular carcinoma in Caucasian chronic hepatitis B (CHB) patients under long-term therapy with entecavir or tenofovir disoproxil fumarate - (12/17/18)   Economic Burden of Progression to Cirrhosis in Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States - (12/14/18)   Prevalence and Long-term Outcomes of Non-alcoholic Fatty Liver Disease (NAFLD) Among Elderly Individuals from the United States - (12/14/18)   Non-Alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease: The Impact of Alcohol Consumption and Metabolic Syndrome to Mortality - (12/14/18)   NGM282 DEMONSTRATES ANTI-INFLAMMATORY AND ANTI-FIBROTIC ACTIVITIES THAT ARE INDEPENDENT OF STEATOSIS REDUCTION IN A FARNESOIDX RECEPTOR (FXR)-DEFICIENT, DIET-INDUCED ANIMAL MODEL OF NON-ALCOHOLIC STEATOHEPATITIS(NASH) - (12/14/18)   NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis(NASH) Results of a Phase 2 Multi-Center Dose Finding Study - (12/14/18)   Interim results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with PEG-IFNα in patients with chronic HBV/HDV co-infection - (12/12/18)   One-year results of the Global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol, a Stearoyl CoA Desaturasemodulator in NASH patients - (12/12/18)   FIBROSIS REGRESSION OBSERVED IN TREATMENT WITH FGF19 VARIANTS INA DIET INDUCED MOUSE MODEL OF NASH IS PREDOMINANTLY MEDIATED BY FGFR4 ACTIVITY AND INDEPENDENT OF WEIGHT LOSS OR DECREASES IN HEPATIC STEATOSIS - (12/12/18)   NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis(NASH) Results of a Phase 2 Multi-Center Dose Finding Study - (12/12/18)   NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study - (12/12/18)   NGM313, a Novel Once-Monthly Activator of bKlotho-FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Non- Alcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin-Resistant Patients with NAFLD - (12/12/18)   GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor, Reduces Plasma Acylcarnitines in Patients With Nonalcoholic Steatohepatitis - (12/11/18)   Validation of Fractional Synthesis Rate of Plasma Lumican as a Noninvasive Marker of Fibrogenesis in Patients With Nonalcoholic Steatohepatitis - (12/11/18)   The Incidence of Malignancies in Nonalcoholic Fatty Liver Disease - (12/11/18)   Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions With the Acetyl-CoA Carboxylase Inhibitor GS-0976, and Phenotypic Probe Substrates and Inhibitors - (12/11/18)   Early adoption of tenofovir alafenamide (TAF) for Hepatitis B in US clinical practice; real-world evidence from the TRIO network - (12/11/18)   Treatment of hepatitis B in the US; real-world evidence from the TRIO network - (12/11/18)   Prevalence of Chronic Hepatitis C Virus Infection US States and District of Columbia, 2013-2016 - (12/10/18)   A REAL WORLD RESISTANCE PROFILE OF VIROLOGIC FAILURES COLLECTED FROM AN INTERNATIONAL COLLABORATION (SHARED) - (12/10/18)   Prevalence of NS3 and NS5A resistance associated substitutions through European DAA-failures - (12/10/18)   The prevalence of hepatitis C virus NS5A polymorphisms in Europe - (12/10/18)   Disparities in Accessing HCV Care under Medicaid Programs Across the US; Experience from the TRIO Network - (12/10/18)   The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM) - (12/10/18)   Alteration of Hepatic OATP Activity Does Not Alter the Pharmacodynamic Effect of GS-0976, a Liver-Targeted ACC Inhibitor, on De Novo Lipogenesis - (12/07/18)   Association Between Apolipoprotein C3 and Serum Triglycerides in Nonalcoholic Steatohepatitis Patients Treated With the Acetyl-CoA Carboxylase Inhibitor GS-0976 - (12/07/18)   ASK1 Inhibition Reduces Progression of Liver Cirrhosis and Prevents Tumor Development in the BALB/c.Mdr2-/- Mouse Model of Biliary Fibrosis - (12/07/18)   Hepatic Protease Expression in Patients With NASH Correlates With Fibrosis Stage and Treatment Response in a Phase 2 Trial of Selonsertib - (12/07/18)   Hepatic Metabolomics and Plasma MicroRNA Analysis of Combinations of an ASK1 Inhibitor, an ACC Inhibitor, and an FXR Agonist in a Rat Choline-Deficient High-Fat Diet Model Reveal Reductions in Oxidative Stress, Inflammation, and Fibrosis - (12/07/18)   DAA HCV Retreatment Studies at AASLD 2018 - (12/07/18)   ABIDE : A novel predictive model of liver decompensation in patients with non-alcoholic fatty liver related cirrhosis - (12/04/18)   Severity of NAFLD/NASH is associated with both more severe β-cell dysfunction and reduced insulin clearance independently of body weight in a large cohort of non-diabetic subjects: further insights in the causative role of NASH in T2DM development - (12/04/18)   Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database - (12/04/18)   The Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Ascites and Hepatocellular Carcinoma Development in a Rat Model of Cirrhosis - (12/04/18)   Diet Reduced Chronic Liver Disease Death by 50% - Association of high-quality diets with reduced chronic liver disease mortality: diet quality index analyses in the Multiethnic Cohort - (12/04/18)   Trends in hospital admissions and cost in cirrhotic patients with diverse etiologies and ethnicities in the U.S. from 2005 to 2015: 'NAFLD admissions tripled' - (12/03/18)   Risk of Cirrhosis and Hepatocellular Cancer in Patients with Nonalcoholic Fatty Liver and Normal ALT - (12/03/18)   NIS4 for detection of active NASH (NAS≥4) and significant fibrosis (F≥2) in 714 patients at risk of NASH: Diagnostic Metrics Are Not Affected By Age, Gender, Type 2 Diabetes or Obesity - (12/03/18)   Prevalence and Long-term Outcomes of Non-alcoholic Fatty Liver Disease (NAFLD) among Lean Individuals without Any Components of Metabolic Syndrome - (12/03/18)   First direct comparison in NAFLD of the blood fibrosis tests FibroMeter and ELF - (12/03/18)   FibroScan-based score to identify NASH patients with NAS≥4 and F≥2 - (12/03/18)   Impact of Pre-Screening with Fibrosis-4 Index on a Referral Pathway for Patients with Suspected NAFLD - (12/03/18)   Physical Activity and Risk of Mortality in Nonalcoholic Fatty Liver Disease: A Population Based Study (NHANES III) of United States Adults - (12/03/18)   Feasibility of Using Deep-Learning Techniques to Assess Hepatic Fibrosis Directly from Magnetic Resonance Elastography Source Images - (11/30/18)   The Pharmacokinetics of GS-0976, an Acetyl-CoA Carboxylase Inhibitor, in Subjects With Mild, Moderate, and Severe Hepatic Impairment - (11/30/18)   Advanced Fibrosis Based on Noninvasive Tests in Nonalcoholic Steatohepatitis (NASH) Is Associated with Impairment of Patient-Reported Outcomes - (11/30/18)   Algorithms Using Noninvasive Tests Can Accurately Identify Patients With Advanced Fibrosis Due to NASH: Data From the STELLAR Clinical Trials - (11/30/18)   Selonsertib in Combination with Prednisolone for the Treatment of Severe Alcoholic Hepatitis: A Phase 2 Randomized Controlled Trial - (11/30/18)   Limited sustained response and lack of HBsAg decline after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results of the prospective, randomized, open-label phase IV STOP study - (11/28/18)   Limited sustained response and lack of HBsAg decline after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results of the prospective, randomized, open-label phase IV STOP study - (11/28/18)   Endothelial function worsens with hepatitis C direct-acting antiviral treatment despite improvements in systemic measures of inflammation - (11/28/18)   Baseline Polymorphisms and Phylogeographic Analysis of NS3, NS5A, and NS5B in HCV Genotype 1b-Infected Chinese Patients Enrolled in ONYX-1 - (11/28/18)   Clinical Benefits, Economic Savings and Faster Time to HCV Elimination with a Simplified 8-Week Treatment and Monitoring Program in Chronic F0-F3 Naïve Patients in the US - (11/28/18)   Effectiveness and Safety of DAA Treatment for CHC Patients with Previous HCC: A REAL-C Study - (11/28/18)   The effect of semaglutide on liver enzymes in subjects with obesity and elevated alanine aminotransferase: data from a randomized phase 2 trial - (11/28/18)   Drug-Drug Interaction Potential of Glecaprevir/Pibrentasvir Based on Real-World Medication Use in Patients With Chronic Hepati tis C Virus Infection: Data From the German Hepatitis C-Registry (DHC-R) and PAN-Cohort - (11/27/18)   Effectiveness of Sofosbuvir / Velpatasvir in Treating Hepatitis C Virus Infection in Real-world Setting / IDUs, British Columbia - (11/27/18)   In a Placebo Controlled 36 Week Phase 2 Trial, Treatment with MGL-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in NASH on Serial Liver Biopsy - (11/27/18)   Tropifexor (TXR), an FXR Agonist for the Treatment of NASH - Interim Results from First Two Parts of Phase 2b Study FLIGHT-FXR - (11/27/18)   GLECAPREVIR/PIBRENTASVIR ADMINISTERED FOR 8 WEEKS RESULTS IN EXCELLENT EFFECTIVENESS AND SAFETY: A REAL-LIFE STUDY ON 639 ITALIAN HCV PATIENTS FROM THE NAVIGATOR LOMBARDIA NETWORK - (11/26/18)   "Treatment of Genotype 3 Cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: Real life experience from Italy" - (11/26/18)   Improved Short-Term Survival in HCV Seropositive Kidney Transplant Recipients during the DAA Era in the United States - (11/26/18)   Uptake of and factors associated with direct-acting antiviral therapy among patients in the CHeCS, 2014-2017 - (11/26/18)   Risk-Based HCC Surveillance Strategies Using HCC Risk Prediction Models Have Greater Net Benefit Than the Current "One-Size-Fits-All" Strategy In Patients who Received Antiviral Treatment for HCV - (11/26/18)   NAFLD Debrief 2018 AASLD November 13, 2018, San Francisco, CA - (11/20/18)   High SVR in PWID with HCV Despite Imperfect Medication Adherence: Data from the ANCHOR Study - (11/20/18)   The Hepatitis C Continuum of Care for People Who Inject Drugs; Philadelphia, PA - young PWID 8% treated for HCV, older still only 25% - (11/20/18)   VITAMIN E IS AN EFFECTIVE TREATMENT FOR NASH IN HIV MONO-INFECTED PATIENTS: THE CTN-PT 024 TRIAL - (11/20/18)   TLR7 agonist RO7020531 triggers immune activation after multiple doses in chronic hepatitis B patients - (11/20/18)   First results with RNA interference (RNAi) in chronic hepatitis B (CHB) using ARO-HBV - (11/20/18)   FINAL RESULTS OF A PHASE 1B 28-DAY STUDY OF ABI-H0731, A NOVEL CORE INHIBITOR, IN NON-CIRRHOTIC VIREMIC SUBJECTS WITH CHRONIC HBV - (11/20/18)   Preemptive DAA Therapy in Donor HCV-positive to Recipient HCV-negative Cardiac Transplantation - (11/19/18)   HCV-RNA Is Readily Detectable in Nasal and Rectal Fluids of HCV Patients with High Viremia - (11/19/18)   Hepatitis Debrief: The Liver Meeting 2018 - (11/19/18)   Safety, Pharmacokinetics, and Immunogenicity of BMS-986263/ND-L02-s0201 in Healthy Japanese and Non-Japanese Participants - (11/19/18)   Risk of Incident Diabetes in Hepatitis C Patients Following Completion of Direct-acting Antiviral Therapy - (11/19/18)   The impact of HCV SVR from direct acting antiviral and interferon-based treatments on mortality in a large population based cohort study - (11/19/18)   Hepatitis C Risk-Based vs. Universal Screening Among Pregnant Women: Implementation and Cost-Effectiveness Analysis - (11/19/18)   Direct Antiviral Agents after Successfully Treated Early Hepatocellular Carcinoma Improve Survival in Cirrhotic Patients with Chronic Hepatitis C - (11/19/18)   Safety, Pharmacokinetics and Antiviral Activity of Novel HBV Capsid Assembly Modulator, JNJ-56136379, in Patients with Chronic Hepatitis B - (11/19/18)   Cenicriviroc Treatment over 2 Years Results in Clinically Meaningful and Sustained Improvement in Fibrosis in Adults with Nonalcoholic Steatohepatitis and Severe Liver Fibrosis - (11/16/18)   Sustained Virologic Response Reduces the Incidence of Extrahepatic Manifestations in Chronic Hepatitis C Infection - (11/16/18)   Impact of Baseline HCV RNA Levels as Assessed by 2 Different Assays on the Efficacy of 8-Week Glecaprevir/Pibrentasvir in Patients With HCV GT1-6 Infection - (11/16/18)   Risk of Cardiovascular Disease Events after HCV Treatment: Results from ERCHIVES - (11/16/18)   Rising and Higher Healthcare Resource Utilization (HCRU) and Costs of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH) Patients with Advanced Liver Disease of Increasing Severity - Results of a US Real-World Analysis - (11/16/18)   Effectiveness of 8-week glecaprevir/pibrentasvir(G/P) for treatment naïve, non-cirrhotic patients with HCV infection in the TRIO Health network - (11/16/18)   Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Prior Treartment Failures with Glecaprevir/Pibrentasvir (G/P) in Chronic Hepatitis C Infection - (11/16/18)   REAL-WORLD SAFETY AND EFFECTIVENESS OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR AND GLECAPREVIR/PIBRENTASVIR IN HEPATITIS C INFECTED PATIENTS - (11/16/18)   HEPATITIS C VIRUS REINFECTION AND INJECTING RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR TREATMENT IN PARTICIPANTS ON OPIATE AGONIST THERAPY: C-EDGE CO-STAR PART B - (11/16/18)   Pharmacokinetics of Once-Daily Sofosbuvir or Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 3-<6 Years - (11/16/18)   Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Children 3 to <6 years old with Chronic Hepatitis C Virus Infection - (11/16/18)   Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Chronic HCV Infection and Moderate to Severe Renal Impairment: An Integrated Analysis - (11/16/18)   Durability of Sustained Virologic Response and Liver-Related Safety in Patients Treated With Glecaprevir/Pibrentasvir: A Long-Term Follow-Up Study - (11/16/18)   Sofosbuvir / Velpatasvir / Voxilaprevir in DAA Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program - (11/16/18)   Retreatment with voxilaprevir/velpatasvir/sofosbuvir in patients with chronic hepatitis C virus infection and prior DAA failure - results from the German Hepatitis C-Registry (DHC-R) - (11/16/18)   Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results From a Phase 3 Clinical Trial - (11/16/18)   High SVR in PWID with HCV Despite Imperfect Medication Adherence: Data from the ANCHOR Study updated - (11/16/18)   ASK1 Inhibition Reduces Progression of Liver Cirrhosis and Prevents Tumor Development in the BALB/c.Mdr2-/- Mouse Model of Biliary Fibrosis - (11/16/18)   Routinely Available Noninvasive Tests Discriminate Advanced Fibrosis Due to NASH in the Phase 3 STELLAR Trials of the ASK1 Inhibitor Selonsertib - (11/16/18)   GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor, Reduces Plasma Acylcarnitines in Patients With Nonalcoholic Steatohepatitis - (11/16/18)   The Nonsteroidal FXR Agonist GS-9674 Leads to Significant Reductions in Hepatic Steatosis, Serum Bile Acids, and Liver Biochemistry in a Phase 2, Randomized, Placebo-Controlled Trial of Patients With NASH - (11/16/18)   The Nonsteroidal Farnesoid X Receptor Agonist GS-9674 Improves Liver Biochemistry and Decreases Serum Bile Acids in Patients with Primary Sclerosing Cholangitis: A Phase 2, Randomized, Placebo-Controlled Trial - (11/16/18)   Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results From a Phase 3 Clinical Trial - (11/19/18)   Incidence and Predictors of de Novo Hepatocellular Carcinoma Following Achievement of Sustained Virologic Response With Direct-Acting Antivirals: Results From the Gilead SVR and Cirrhosis Registries - (11/14/18)   Retreatment with SOF/VEL/VOX in Treatment-Experienced Patients with and without HIV: The RESOLVE Study - (11/14/18)   Effectiveness of Elbasvir/Grazoprevir in Black Persons With Genotype 1 Hepatitis C Virus - (11/14/18)   Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks in Participants With Hepatitis C Virus Genotype 4 Infection - (11/14/18)   Utilization and Effectiveness of Elbasvir/Grazoprevir for the Treatment of Hepatitis C Virus Genotype 1b Infection: Updated Cohort From the US Veteran Affairs Healthcare System - (11/14/18)   Sofosbuvir/Velpatasvir for Patients With Chronic Genotype 3 HCV Infection With Compensated Cirrhosis: an Integrated Analysis of Phase 2 and Phase 3 Clinical Trials - (11/14/18)   Effectiveness of Sofosbuvir/Velpatasvir for 12 Weeks in HCV Genotype 3 Patients with Compensated Cirrhosis in Clinical Practice Cohorts from Around the World - (11/14/18)   Sustained Viral Response Following Treatment With Direct-Acting Antiviral Regimens Is Durable in More Than 6600 Patients: Results of the Gilead Sustained Virologic Response Registry Study - (11/14/18)   Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 - (11/14/18)   Response-Guided Therapy with DAA Shortens Treatment Duration in 50% of HCV Treated Patients - (11/14/18)   Early Treatment with Direct-Acting Antivirals Saves Medical Costs in Non-Cirrhotic Patients with Chronic Hepatitis C Virus Infection in the United States - (11/14/18)   Changes in the characteristics of hepatitis C patients treated with direct-acting antivirals from 2014-2017 - (11/13/18)   Nivolumab in Patients With Child-Pugh B Advanced Hepatocellular Carcinoma in the CheckMate040 Study - (11/13/18)   Changes in the characteristics of hepatitis C patients treated with direct-acting antivirals from 2014-2017 - (11/13/18)   Short-Duration Sofosbuvir/Velpatasvir Safe and Effective in Treating HCV Infection Immediately After Liver Transplant - (11/13/18)   Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5 or 6 Infection: Final Results of the ENDURANCE-5,6 Study - (11/13/18)   Changing Cascade of Care for Hepatitis C in the Era of Direct-Acting Antivirals - (11/13/18)   Quality of Life in Patients with Psychiatric Disorders: Pooled Analysis from Glecaprevir/Pibrentasvir Registrational Studies - (11/13/18)   Real-World Effectiveness of Glecaprevir/Pibrentasvir in 1,941 Patients with Hepatitis C Genotypes 1 through 4 - (11/13/18)   Lower Likelihood of Graft Failure and Death after Liver Transplantation in the Era of Current Direct Acting Antivirals: An Analysis of the 2002-2018 United Network for Organ Sharing Registry - (11/13/18)   Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the U.S. - (11/13/18)   High efficacy of glecaprevir/pibrentasvir in patients with chronic HCV GT1 infection who failed prior treatment with NS5A-inhibitor plus sofosbuvir regimens - (11/13/18)   Sofosbuvir/Velpatasvir for 12 Weeks Is Safe and Effective in Patients Undergoing Dialysis - (11/13/18)   The impact of HCV SVR from direct acting antiviral and interferon-based treatments on mortality in a large population based cohort study - (11/13/18)   PRELIMINARY EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 1-6 INFECTION AND COMPENSATED CIRRHOSIS: THE EXPEDITION-8 STUDY - (11/13/18)   Real World Effectiveness of Sofosbuvir/velpatasvir/voxilaprevir in 573 Treatment-Experienced Patients with Hepatitis C - (11/13/18)   High SVR in PWID with HCV Despite Imperfect Medication Adherence: Data from the ANCHOR Study - (11/13/18)   Retreatment with SOF/VEL/VOX in Treatment-Experienced Patients with and without HIV: The RESOLVE Study - (11/13/18)   Incidence of Hepatocellular Carcinoma Among Patients With Hepatitis C Virus Infection Following Treatment With a Grazoprevir-Containing Regimen - (11/13/18)   Real-World Impact of Resistance-Associated Substitutions on Re-Treatment after Ledipasvir/Sofosbuvir Virologic Failure in Hepatitis C Patients (VA) - (11/13/18)   The Medicines Patent Pool Signs Licence with AbbVie to Expand Access to Key Hepatitis C Treatment, Glecaprevir/Pibrentasvir - (11/13/18)   Universal HCV Screening on the Way? - (11/13/18)   Real-life effectiveness and safety of velpatasvir/sofosbuvir/voxilaprevir for previously DAA treated patients with chronic hepatitis C - (11/13/18)   Sofosbuvir/velpatasvir/voxilaprevir(SOF/VEL/VOX) in care of chronic hepatitis C patients; clinical practice experience from the TRIO network - (11/13/18)   Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection: Updated Real-World Data From the German Hepatitis C-Registry - (11/11/18)   National Estimates for HCV Screening and Diagnosis Rates in the United States (2013-2016) Based on a Large Real-World Dataset - (11/11/18)   National Examination of HCV Linkage to Care in the United States (2013-2016) Based on Large Real-World Dataset - (11/09/18)   Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018 - (11/09/18)   Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018 - (11/09/18)   Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018 - (11/09/18)   AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape in the United States Using Comprehensive Dataset - (11/09/18)